Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730299 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
A Phase 3 study, sponsored by Gamida Cell.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT02730299 is a Phase 3 study that has completed, run by Gamida Cell. The registered enrollment target is 125 participants.
The verdict
NCT02730299, a Phase 3 study, has completed, sponsored by Gamida Cell.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia or lymphoma, all with required disease features rendering them eligible for allogeneic transplantation.
Interventions
- DRUG NiCord® (omidubicel)
- OTHER Cord Blood Unit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2025-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730299
The ClinicalTrials.gov registry entry for NCT02730299 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NiCord® (omidubicel) is the first listed.
NCT02730299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730299 about?
NCT02730299 is a clinical study titled "Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS". This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, myelodysplastic syndr...
What is the current status of trial NCT02730299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2016-12-16. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT02730299?
The interventions under investigation include: NiCord® (omidubicel) (DRUG), Cord Blood Unit (OTHER).
Who is sponsoring clinical trial NCT02730299?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.